Similar articles

• Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey.

  Velati C, Romanò L, Fomiatti L, Baruffi L, Zanetti AR; SIMTI Research Group. Velati C, et al. Transfusion. 2008 Oct;48(10):2205-13. doi: 10.1111/j.1537-2995.2008.01813.x. Epub 2008 Jul 8. Transfusion. 2008. PMID: 18631163
• Residual risk of transfusion-transmitted human immunodeficiency virus, hepatitis C virus, and hepatitis B virus infections in Italy.

  Gonzalez M, Règine V, Piccinini V, Vulcano F, Giampaolo A, Hassan HJ. Gonzalez M, et al. Transfusion. 2005 Oct;45(10):1670-5. doi: 10.1111/j.1537-2995.2005.00576.x. Transfusion. 2005. PMID: 16181219
• Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus.

  Hourfar MK, Jork C, Schottstedt V, Weber-Schehl M, Brixner V, Busch MP, Geusendam G, Gubbe K, Mahnhardt C, Mayr-Wohlfart U, Pichl L, Roth WK, Schmidt M, Seifried E, Wright DJ; German Red Cross NAT Study Group. Hourfar MK, et al. Transfusion. 2008 Aug;48(8):1558-66. doi: 10.1111/j.1537-2995.2008.01718.x. Epub 2008 May 6. Transfusion. 2008. PMID: 18466173
• PHS guidelines for management of occupational exposure to HBV, HCV and HIV: management of occupational blood exposures.

  Preboth M. Preboth M. Am Fam Physician. 2001 Dec 15;64(12):2012-4. Am Fam Physician. 2001. PMID: 11775767 Review. No abstract available.
• Residual risk of transfusion transmitted viral infections among seronegative donors: application of the incidence/window period model.

  Kleinman S. Kleinman S. Dev Biol (Basel). 2000;102:61-5. Dev Biol (Basel). 2000. PMID: 10794091 Review. No abstract available.